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Background: Urinary tract infections (UTIs) are among the most prevalent microbial
diseases and their financial burden on society is substantial. The continuing increase
of antibiotic resistance worldwide is alarming so that well-tolerated, highly effective
therapeutic alternatives are urgently needed.
Objective: To investigate the effect of bacteriophages on Escherichia coli and Klebsiella
pneumoniae strains isolated from the urine of patients suffering from UTIs.
Material and methods: Forty-one E. coli and 9 K. pneumoniae strains, isolated from
the urine of patients suffering from UTIs, were tested in vitro for their susceptibility toward
bacteriophages. The bacteriophages originated from either commercially available
bacteriophage cocktails registered in Georgia or from the bacteriophage collection of the
George Eliava Institute of Bacteriophage, Microbiology and Virology. In vitro screening of
bacterial strains was performed by use of the spot-test method. The experiments were
implemented three times by different groups of scientists.
Results: The lytic activity of the commercial bacteriophage cocktails on the 41 E. coli
strains varied between 66% (Pyo bacteriophage) and 93% (Enko bacteriophage).
After bacteriophage adaptation of the Pyo bacteriophage cocktail, its lytic activity
was increased from 66 to 93% and only one E. coli strain remained resistant. One
bacteriophage of the Eliava collection could lyse all 9 K. pneumoniae strains.
Conclusions: Based on the high lytic activity and the potential of resistance
optimization by direct adaption of bacteriophages as reported in this study, and in view
of the continuing increase of antibiotic resistance worldwide, bacteriophage therapy is a
promising treatment option for UTIs highly warranting randomized controlled trials.
Keywords: bacteriophages, antibiotics, urinary tract infection, bacteriophage adaptation, antibiotic resistance
Abbreviation: AM, ampicillin; AMC, amoxicillin/clavulanic acid; CIP, ciprofloxacin; CL, confluent lysis; CXM, cefuroxime;
E. coli, Escherichia coli; ESBL, extended spectrum beta lactamase; EUCAST, European Committee on Antimicrobial
Susceptibility Testing; F, female; I, intermediate; IP, individual clear or opaque plaques; K. oxytoca, Klebsiella oxytoca;
K. pneumonia, Klebsiella pneumoniae; M, male; n, no (absent); ND, not done; NF, nitrofurantoin; NOR, norfloxacin;
OL, overgrown lysis; P. aeruginosa, Pseudomonas aeruginosa; R, resistant; S, sensitive; SCL, semi-confluent lysis; SXT,
sulfamethoxazole/trimethoprim or co-trimoxazole; tv, taches vierges; UTIs, urinary tract infections; y, yes (present).
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INTRODUCTION
Urinary tract infections (UTIs) are among the most prevalent
bacterial infections and their financial burden for the society
is substantial. In the USA alone, UTIs are responsible for
over 7 million physician visits annually (Foxman, 2002) and
approximately 15% of all community-prescribed antibiotics are
used for UTIs resulting in an annual cost in excess of 1 billion
US dollars (Mazzulli, 2002). UTIs account for more than 100’000
hospital admissions annually in the USA (Foxman, 2002), most
often for pyelonephritis. These infections are held responsible
for at least 40% of all hospital-acquired infections, and the
majority of cases are catheter-associated (Rüden et al., 1997).
The wide and often uncritical use of antibiotics contributes to
the global increase in resistant strains and the present state of
microbial resistance is alarming (Carlet et al., 2011; Verbeken
et al., 2014). Thus, there is an urgent need for effective, well-
tolerated therapeutic alternatives.
After the discovery of bacteriophages by d’Hérelle in 1917,
the use of bacteriophage therapy was proposed in the 1920s
and has a long and colorful history. At present, bacteriophage
therapy is a registered medicine in East European countries
like Georgia, Armenia, Ukraine, and Russia, and well accepted
by physicians and patients. Several researchers (Abedon et al.,
2011; Chanishvili, 2012) have reviewed numerous examples of
successfully applied bacteriophage therapy for a diverse area of
medical specializations, including dermatology, surgery, wound
treatment, intestinal infections, ophthalmology, gynecology and
urology. In the Western world bacteriophages have been
approved as food processing aid for the decontamination of
food (e.g., ListShieldTM). However, the use of bacteriophages
as treatment against selected bacterial infectious diseases
has not yet been approved by regulatory authorities and a
regulatory framework is still missing (Pirnay et al., 2011,
2015). Nevertheless, the interest from Western clinicians to
collaborate with specialists in bacteriophage therapy is rising, as
is illustrated by the growing number of scientific papers in peer
reviewed journals, for instance regarding the identification of
bacteriophages against the O104:H4 E. coli outbreak in Germany,
(Merabishvili et al., 2012) and the treatment of P. aeruginosa
and Staphylococcus aureus infections in burn wound patients
(Merabishvili et al., 2013). In addition, a number of recent reviews
have addressed the safety of bacteriophage therapy (Kutter et al.,
2010; Pirnay et al., 2015).
Technically, bacteriophage therapy involves the application
of bacteriophages that, upon encounter with specific
pathogenic bacteria, can infect and kill the pathogenic bacteria.
Bacteriophages can specifically dock on bacteria (host species),
introduce their DNA, multiply by using the host cell machinery
bacteria, and subsequently lyse the bacteria with release of virion
progeny that can re-initiate the cycle. In this way, bacteriophages
are unique among antibacterial agents in their ability to increase
their numbers in the presence of specific bacterial targets.
Bacteriophages might be rather appropriate means to treat
patients suffering from UTIs: compared to last generation of
antibiotics, bacteriophages are relatively cheap and the treatment
can be done under the control of medical personnel by using
a catheter for intravesical instillation several times a day. In
addition, bacteriophage therapy for UTI treatment will be applied
locally and does not involve a systemic treatment. It is also
likely that the absence of physical and metabolic barriers in
this kind of treatment increases the potential efficacy and
reduces the occurrence of potential adverse events. Thus, in
view of the high prevalence of UTIs, the continuing increase of
antibiotic resistance worldwide, and the renewed interest to apply
bacteriophage therapy in the Western world, we investigated
the effect of bacteriophages on E. coli and K. pneumoniae
strains isolated from the urine of patients suffering from
UTIs.
MATERIALS AND METHODS
Information on Bacterial Strains and
Patients
Between February 2012 and January 2013, 41 E. coli and 9
K. pneumoniae strains were isolated from urinary cultures of 50
patients (22 women and 28 men) suffering from UTIs defined
according to the European Association of Urology Guidelines on
Neuro-Urology (Groen et al., 2016). Urine samples were collected
by sterile catheterization at the Balgrist University Hospital
Zürich and sent within 16 h to the microbiological laboratory
of the University of Zürich, Switzerland. None of the patients
received antibiotic treatment within 4 weeks before urinary
culture. The mean age of the 50 patients was 55 ± 18 years.
The causes of lower urinary tract dysfunction were spinal cord
injury in 38 (76%), multiple sclerosis in 8 (16%) and spinal
stenosis in 4 (4%) patients. Of the 50 patients, 34 (68%) relied
on aseptic intermittent self-catheterization, 12 (24%) on an
indwelling (transurethral n = 4, suprapubic n = 8) catheter and
4 (16%) voided spontaneously.
The urine samples were cultivated on sheep blood agar
(COS, bioMérieux, Marcy l’Etoile, France), on sheep blood agar
with colistin and nalidixic acid (CNA, bioMérieux) and on the
chromogenic agar (Uriselect 4, Bio-Rad, Marnes – la Coquette,
France). The isolated bacteria were identified according to
standard procedures. The susceptibility testing was performed
according to the EUCAST Version 3.1, 2013 (www.eucast.org).
The strains were stored at −70◦C in skimmed milk. Before
shipping to Georgia, the isolated strains were sub-cultured and
transferred to Amies transport agar (Copan, Brescia, Italy).
Bacteriophages
Four commercial bacteriophage preparations registered in
Georgia, Pyo, Intesti, Ses, and Enko bacteriophages, along
with 29 E. coli and 10 K. pneumoniae bacteriophages from
the bacteriophage collection of the George Eliava Institute
of Bacteriophage, Microbiology and Virology, were used in
a bacterial cell lysis screening assay. In order to eliminate
effects of batch to batch variations, the individual bacteriophage
preparations used for the screening came from the same
production batch. The bacteriophages composing the four
commercial bacteriophage preparations were grown on a set of
bacterial strains, and underwent titration by Appelmans method
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(Appelmans, 1921) on each individual strain previously used for
multiplication of the bacteriophages. In agreement with current
regulation the average titer of the mixture is 10−4–10−5 for at
least 48 h (Appelmans method), which corresponds to titers of
107–109 pfu/mL.
The individual bacteriophages have been selected on basis
of their capability to eliminate currently prevailing pathogenic
microorganisms in Georgia, including E. coli, P. aeruginosa,
Staphylococcus spp., Shigella spp., Salmonella spp., Enterococcus
spp., and Proteus spp. More information of the composition and
origin of the four bacteriophage preparations can be found in
earlier work on Pyo and Intesti (Abedon et al., 2011) and Ses and
Enko (Fitzgerald-Hughes et al., 2014).
The 29 E. coli bacteriophages were freshly prepared and
originally isolated for their potential as antimicrobial agents
for therapeutical applications from a broad range of different
sources during the period 2000–2012, like sewage waters,
agricultural farm isolates (Khurtsia et al., 2001) and clinical
isolates (Ghudumidze et al., 2012).
The 10 K. pneumoniae bacteriophages (Table 3) were isolated
between 2002 and 2012 from sewage samples (Karumidze et al.,
2013) with the aim to treat patients suffering from UTIs and
prostatitis using clinical K. pneumoniae strains or K. oxytoca
strains as hosts. All bacteriophages used in this study were lytic
bacteriophages, as was concluded on basis of a combination of
analyses and observations, including plaque morphology and
clarity of lytic zones on the lawn of bacterial agar, host range, time
to infection, time of latent period, and concentration of progeny
(Clokie and Kropinski, 2009).
Screening
Screening of bacterial strains for susceptibility to bacteriophages
was performed by using a spot test method (Craigie and Yen,
1938) and then modified by different authors and adjusted for
different species (Felix and Callow, 1943; Felix, 1956). Bacterial
cultures were grown overnight (18–24 h at 37◦C) to receive
a concentration of 109 colony forming units (cfu) mL−1 and
diluted 10 times up to a final concentration of 108 cfu mL−1.
100 µL of the diluted culture was transferred into 2–3 mL
of previously melted and cooled soft agar (0.7% Brain-Heart
agar), vortexed for 30–60 s and poured on the top of solidified
and previously dried Petri dishes containing 2% of Brain-Heart
agar. After solidification of the top agar (30–60 min) at room
temperature, 10 µL of bacteriophage suspension with a titer of
FIGURE 1 | Plaque morphology of Escherichia coli strain #33. The figure shows overgrown (partial) lysis (OL) in case of Pyo and Intesti bacteriophages and
confluent (complete) lysis (CL) in case of Ses and Enko bacteriophages. All these results are positive.
Frontiers in Microbiology | www.frontiersin.org 3 April 2016 | Volume 7 | Article 465
fmicb-07-00465 April 7, 2016 Time: 14:42 # 4
Sybesma et al. Bacteriophages as a Promising Treatment Option for UTIs
107 plaques forming units (pfu) mL−1 was placed on top of the
soft agar using an automatic pipette. The plates were let to dry
for 20–30 min and then incubated overnight (18–24 h) at 37◦C.
Next, the results were visually evaluated.
Primary Outcome Measure
The primary outcome measure was the assessment of lytic activity
of the bacteriophages on the bacteria, as could be identified by
the plaque morphology in a double-layered plaque assay using
E. coli or K. pneumoniae strains. A bacterial lawn inoculated
with a range of bacteriophages gives different visual patterns,
similar to a bacteriophage typing pattern and depending on
the effect of the bacteriophage-host strain interaction. The
clear zones usually differ by their intensity and structure
(Figures 1 and 2). The positive reactions were classified as
“CL” – confluent lysis, i.e., a full clear zone on the well-
developed lawn of bacterial culture; “SCL” – semi-confluent lysis,
i.e., a not fully cleared bacterial lawn; “OL” – overgrown lysis,
i.e., single bacterial colonies that overgrew a complete clear
zone; “IP” – individual clear or opaque plaques, which look
like multiple small clear zones on the bacterial lawn within
a drop contour, previously assigned by d’Hérelle as “tv” from
“taches vierges” (Clokie and Kropinski, 2009; Chanishvili, 2012).
The negative reactions were classified as “R” – resistant, i.e.,
no lysis.
Extension and Optimisation of the
Bacteriophage Preparation Host-Range
(Adaptation)
Expansion of the range of lytic activity of the Pyo bacteriophages
cocktail was achieved by selection of mutant bacteriophages
with extended host-range (h-mutants) and by increasing their
titers in the bacteriophage preparation. For this purpose the
bacteriophages were propagated in a suspension containing the
bacterial cultures of choice with low or no susceptibility to
these bacteriophages. The initial steps of adaptation technique
are similar to Appelmans’ method for titration in liquid media
(Appelmans, 1921). The adapted bacteriophages were used for
the repeated screening.
RESULTS
The antibiogram of the 41 E. coli and 9 K. pneumoniae
strains shows the ESBL production capability of the strains
and their sensitivity or resistance for each of seven tested
FIGURE 2 | Plaque morphology of E. coli strain #16. The figure shows individual plaques (IP) in case of Pyo and Intesti bacteriophages and two degrees of
overgrown (partial) lysis (OL) in case of Ses and Enko bacteriophages. All these results are positive.
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antibiotics, Table 1. In summary, the strain susceptibility
varies between sensitive for all antibiotics to resistant for at
least six of the seven tested antibiotics. The lytic (killing)
activity of the commercial bacteriophage cocktails on the 41
E. coli strains varied between 66% (27 strains sensitive for
Pyo bacteriophages) and 93% (38 strains sensitive for Enko
bacteriophages), Table 2. From the 29 E. coli bacteriophages from
the Eliava collection, the highest lytic activity came from the
bacteriophages vB_E. coli _4t, vB_E. coli _4s, and vB_E. coli _Pic
with 42, 39, and 24% coverage, respectively. Three of the E. coli
strains (E. coli 5, E. coli 29, and E. coli 35 ESBL) showed complete
resistance to all bacteriophage from any of the 4 commercial
bacteriophage cocktails and 29 E. coli bacteriophages from the
Eliava collection.
However, after adaptation of the Pyo bacteriophages the lytic
activity could be increased from 27 to 38 sensitive strains (66 to
93%, Table 2), including two of the three previously mentioned
resistance strains. In total, all but one E. coli strain could be lysed
by one of the four commercial bacteriophage preparations and
only strain E. coli 35 ESBL remained resistant, even after the
adaptation of the Pyo bacteriophage preparation.
Regarding K. pneumoniae strains (Table 3), the best result
was shown by bacteriophage v_B–KpS10 that could lyse all nine
strains.
Bacteriophage and antibiotic susceptibility/resistance did not
correlate. For example, E. coli strain #33 was resistant to all
tested antibiotics except nitrofurantoin (NF; Table 1), while the
same strain was susceptible to all tested bacteriophages (Table 2,
Figure 1). On the contrary, E. coli strain #35 was resistant to all
tested bacteriophages (Table 2), but showed susceptibility to two
antibiotics, i.e., amoxicillin (AMC) and sulfamethoxazole (SXT;
Table 1).
DISCUSSION
The in vitro lytic activity of bacteriophages has already been
demonstrated in several studies (Chanishvili, 2012) but data
TABLE 1 | Antibiogram of 41 Escherichia coli and 9 Klebsiella pneumoniae strains isolated from the urine of patients suffering from UTIs.
Antibiotic resistance profile
AM AMC CXM SXT NOR CIP NF ESBL
E. coli strain number
3,9,10,13,17,19,21,22, 23,25,27,28,38,39,40 S S S S S S S N
12 S S S S S S R N
11,30 S S S S R R S N
29,36 R S S S S S S N
14,24 R S S S R R S N
8 R S S S I S S N
37 R S S R S S S N
7,16,18,20 R S S R R R S N
1,4 R S R S S S S Y
5 R S R S S S S N
2,31 R S R S R R S Y
15 R S R S R R S N
35 R S R S R R R Y
41 R S R R R R S Y
6 R R S R R R S N
26 R R S I R R S N
32 R R R R S S S Y
33,34 R R R R R R S Y
K. pneumoniae strain number
43 R S S S S S S Y
46,50 R S S S S S S N
42 R S S S S S ND N
48 R S S R S S S N
49 R S R R S S ND Y
47 R S R R R R S Y
44 R S R R I I R N
45 R R R R R R ND Y
Strains were isolated from 22 different women and 28 different men with age between 25 and 80. Numbers 1–41 are E. coli strains with at least 18 different antibiotic
resistance profiles. Numbers 42–50 are K. pneumoniae strains with at least seven different antibiotic resistance profiles. AM, ampicillin; AMC, amoxicillin/clavulanic
acid; CXM, cefuroxime; SXT, sulfamethoxazole/trimethoprim or co-trimoxazole; NOR, norfloxacin; CIP, ciprofloxacin; NF, nitrofurantoin; ESBL, extended-spectrum-beta-
lactamase; Y, yes (present); N, no (absent); R, resistant; S, sensitive; I, intermediate; ND, not done. Notwithstanding the occurrence of several identical antibiograms, all
strains have different bacteriophage resistance/sensitivity profiles, except strains 14 and 24 (compare with Tables 2 and 3).
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TABLE 2 | Results of spot tests on 41 E. coli strains using commercial bacteriophage cocktails.
Strain number Commercial bacteriophage cocktails
Pyo
Before adaptation After adaptation Intesti Ses Enko
39 CL CL CL OL OL
7 IP IP IP OL OL
20 IP OL IP OL OL
6,16 IP SCL IP OL OL
9 OL CL OL OL OL
1 OL CL OL SCL OL
23 OL OL CL OL OL
12,21,33 OL OL OL CL CL
31 OL OL OL IP SCL
4,8,14,24,26,30,34 OL OL OL OL OL
40 OL OL OL SCL OL
28 OL OL SCL CL CL
27,32 OL OL SCL SCL SCL
17 OL OL SCL OL OL
38 OL SCL CL SCL SCL
19 OL SCL OL OL OL
3 R CL OL IP OL
18,36,37 R CL OL OL OL
25 R CL R R OL
15 R CL R SCL OL
22 R CL R SCL SCL
2 R CL SCL SCL CL
5 R IP R R R
10 R IP SCL SCL SCL
11 R R R OL SCL
35 R R R R R
41 R R SCL SCL CL
29 R SCL R R R
13 SCL SCL SCL CL CL
Lytic activity 65.9% 92.7% 82.9% 90.2% 92.7%
CL, confluent lysis; SCL, semi-confluent lysis; OL, overgrown lysis; IP, individual plaques; R, resistant. Twenty-nine unique bacteriophage resistance/sensitivity profiles can
be distinguished.
on the application of bacteriophages for treating UTIs are
scarce (Perepanova et al., 1957; Arshba and Bagdoeva, 1965;
Kolomeitsev et al., 1966; Danilova, 1996; Letkiewicz et al., 2010;
Khawaldeh et al., 2011; Chanishvili, 2012). In the present study
we showed for the first time the lytic activity of commercially
existing bacteriophage cocktails on 41 E. coli strains, isolated from
urinary cultures of patients suffering from UTIs. The applied
spot test demonstrated the results of the bacteriophage–bacteria
interactions: All reactions assigned as CL, SCL, OL, and IP were
positive, which means that the bacteriophages lysed the bacteria,
although with different degrees of effectiveness. In case of CL
the bacteria could not develop bacteriophage resistance during
the incubation period on the plate (18 h), indicating that this
kind of bacteriophage–bacterium interaction can be considered
as the most effective one. The other spot morphologies reflected
less lytic activity, which could partially be caused by the different
concentrations of specific bacteriophages in the commercial
cocktails. Interestingly, our results show a similar order of
lytic activity for the four commercial bacteriophages (before
adaptation) as reported in an earlier bacteriophage sensitivity test
on E. coli strains (Fitzgerald-Hughes et al., 2014). Furthermore,
in the present study, we have shown that, as is common in
the development of bacteriophages, the impact and activity
of the bacteriophage cocktails can be increased in adaptation
experiments, as illustrated by the change from IP into OL, or even
CL (Table 2). The commercial bacteriophage preparations, after
the adaptation experiments of the Pyo bacteriophage cocktail
in successive series of adaptation, showed lytic activity on 40
of the 41 E. coli strains. K. pneumoniae bacteriophages from
the Eliava collection could lyse all of the 9 K. pneumoniae
strains tested. Besides adaptation, the efficacy of bacteriophage
cocktails can also be increased by addition of new bacteriophages
that show lytic activity toward the targeted clinical bacterial
isolate.
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TABLE 3 | Results of spot tests on 9 K. pneumoniae strains using laboratory bacteriophages from the Eliava collection.
Bacteriophages
Strain number vB_KlpR1 vB_KloxR2 vB_KlpR3 vB_KlpR4 vB_KlpR5 vB_KlpR6 vB_KlpR7 vB_KlpR8 v_BR KpM 9 v_BRKpS 10
45,47 R R OL OL R R R R OL OL
42 R R R R R CL R CL OL OL
48 R R R R R R R OL R SCL
50 R R R R R R R R OL OL
43,44,46 R R R R R R R R R OL
49 R R R R R R R R SCL CL
Lytic activity 0% 0% 22% 22% 0% 11% 0% 22% 56% 100%
CL, confluent lysis; SCL, semi-confluent lysis; OL, overgrown lysis; IP, individual plaques; R, resistant. Six unique bacteriophage resistance/sensitivity profiles can be
distinguished.
Since the mode of action of antimicrobial drugs like antibiotics
differs considerably from bacteriophages, resistance mechanisms
are consequently different, as can be concluded by comparing
Table 1 with Tables 2 and 3. Furthermore, these data also
indicate that all but two bacterial strains with a similar antibiotic
resistance profile have different bacteriophage resistance profiles,
which indicates a broader (genetic) variability among the
isolates than could have been expected on the basis of the
antibiotic resistance profiles only. Although beyond the scope
of this study, detailed genetic characterisation could indicate
the effect of bacteriophages on specific serotypes or genotypes
of E. coli and K. pneumonia and determine the spectrum of
the (adapted) bacteriophage cocktails vs. the diversity of the
strains. Full genome sequencing could further reveal which
defense mechanisms by the bacteria and which counter-strategies
by the bacteriophages may have been evolved (Samson et al.,
2013).
The applied bacteriophage cocktails Pyo, Intesti, Ses, and Enko
are allowed by the Georgian medicinal products legislation. In
terms of safety, these bacteriophage preparations are already
commercially available for more than 50 years and have been
used millions of times without relevant incidence of adverse
events. In addition, the bacteriophages in these cocktails are all
lytic and do not have the ability to integrate and remain in the
bacterial genome, contrarily to the temperate bacteriophages that
after infection include their DNA into the host genome without
making much harm to the host (see Materials and Methods).
For a complete overview on quality and safety requirements for
sustainable bacteriophage therapy products see (Pirnay et al.,
2015).
Notwithstanding the potential of application of bacteriophage
therapies in treating patients suffering from UTIs, and its
broad acceptance in some East European countries, one major
limitation today is the regulatory framework in the Western
world (Verbeken et al., 2014; Pirnay et al., 2015), which requires
a long and expensive road of assessments and randomized,
placebo-controlled, double-blind trials. These studies should
also investigate the best routes of administration, duration and
dosage of treatment, adverse events, stability and definition of
formulations and applicability for acute infections. Furthermore,
and in order to accelerate potential regulatory approval for
bacteriophage therapy, bacteriophages should not be considered
in a similar way as chemical drugs, but, because of their typical
mode of action, more like the components of the influenza
vaccine, which is re-evaluated and changed yearly and does not
require clinical trials for each revision (Pirnay et al., 2011). In
addition, it may be appropriate to classify bacteriophages in
different ways for different applications. For example as a drug
for systemic applications, but as a medical device for more topical
applications, as proposed for the treatment of UTIs (Pirnay et al.,
2011). Recently, a set-up has been proposed where bacteriophage
therapy is coordinated and standardized (in a first instance)
by national bacteriophage therapy centers, which operate under
the supervision of relevant public health authorities and in
interaction with private stakeholders (Pirnay et al., 2015).
CONCLUSION
The results of this study have clearly shown the lytic activity of
commercial bacteriophage cocktails on E. coli and K. pneumonia
strains isolated from patients suffering from UTIs. In addition,
the presented data has shown the potential of bacteriophage
adaptation experiments with the aim to increase the lytic activity
of the bacteriophage cocktails.
In times of increasing antibiotic resistance worldwide and in
combination with the long history of safe use of bacteriophages in
East European countries, our findings can be seen as a stimulus
to invest in the set-up of randomized, placebo-controlled trials
and investigate the efficacy of bacteriophage therapies in the
Western world as a common alternative to strictly chemical-
based treatment of bacterial infections.
In view of the high prevalence of UTIs, bacteriophages, as
natural and self-amplifying antibacterial “drugs,” might offer a
non-systemic effective therapeutic option urgently warranting
randomized controlled trials.
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